Introduction
Atherosclerosis is a silent disease that starts in childhood and develops during adolescence and adulthood, causing cardiovascular disease in adults or elderly people. [1] [2] [3] The disease was early detected in fetuses of hypercholesterolemic mothers. 1 The pathogenesis of atherosclerotic disease involves the inflammatory and immune systems. Oxidized low-density lipoprotein cholesterol (LDL-C) accumulates underneath the vascular endothelial cells, resulting in filiform fatty deposits within the vascular intima, which will be covered by a fibrous coat (plaque). This plaque, depending on its stability, may cause ischemic and thrombotic events, such as coronary heart disease and acute myocardial infarction, respectively. 4 Studies on atherosclerosis began through autopsies of young individuals killed in combat. In individuals at mean age 22 years, 45% of the autopsies showed evidence of coronary atherosclerosis, and 5% of these at a severe stage. 2 Pathological and epidemiological studies correlate atherosclerotic lesions and the following risk factors: lipid profile abnormalities, hypertension, hyperglycemia, and obesity. [5] [6] [7] [8] [9] A study involving adolescents showed that modifiable risk factors, such as age, sex, LDL-C levels, high-density lipoprotein cholesterol (HDL-C), triglycerides, smoking, blood pressure, and obesity, are related to atherosclerotic lesions in the coronary and aorta arteries at different grades. These risk factors tend to become more and more important, since they tend to persist and, typically, get worse as age advances. 1 Raitakari et al. 6 followed up 2,229 young adults, aged between 24 and 49 years, who had previously participated in a study of risk factors for atherosclerosis during childhood, at the age of 3-9 years. The authors assessed LDL-C levels, systolic blood pressure and smoking, linking these risk factors to the carotid artery intima-media thickness obtained by ultrasonography at adult life. A linear regression analysis was performed, with correction for age, sex and current risk factors, and a strong association between risk factors at adolescence and an increase in carotid intima-media thickness was found at adult life. 6 Risk factors found at adolescence have higher predictive value than those analyzed on imaging examination at adult life, highlighting the importance of risk factors at early ages. [6] [7] [8] [9] Family history of hypercholesterolemia and cardiovascular disease stands as an important risk factor, which is directly related to lipoprotein levels in children. 10 A Brazilian study identified that, by dividing the obese children by tertiles of homeostasis model of insulin resistance (HOMA-IR), 41 .2% of the patients in the first tertile showed more than two risk factors for cardiovascular disease.
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Increased LDL-C levels may be secondary to inadequate eating habits and lifestyle and/or may occur due to changes in the lipid metabolism resulting from genetic factors. The main representative of lipid metabolic changes in childhood and adolescence is familial hypercholesterolemia. It is characterized by high levels of total and LDL cholesterol, family history of hypercholesterolemia and early death of first-degree relatives due to cardiovascular disease. 12 Considering the increase in the prevalence of childhood obesity, and the consequent increase in the risk of cardiovascular events in a younger population, a new discussion with regard to drug treatment in this population deserves special attention. HDL-C = high-density lipoprotein cholesterol fraction; LDL-C = low-density lipoprotein cholesterol fraction; TC = total cholesterol; TG = triglycerides.
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Dietary guidelines

Prevention
The population-based approach in the guidelines recommends that children over 2 years old adopt a fat and cholesterol-restricted diet which proves appropriate to support their growth and development, in addition to maintaining a "desirable" body weight. Daily recommendation for the general population consists in consuming 300 mg/dL of cholesterol and, at most, 30% of the total energetic value in fat, while only 10% of this value can consist of saturated fat. Currently, consumption of trans fat, which is found in the hydrogenated fat used in the manufacturing of industrialized products, is restricted. 16 Its consumption is directly related to increased concentrations of small-sized LDL-C, which present higher atherogenic risk than the large-sized LDL-C. 16 The American Heart Association (AHA) recommends that the trans fat content in a diet be up to 1% of the total energetic value of lipids. 16 Dietary recommendations include consumption of omega-3-rich fish, two portions a week, since it is associated with reduced risk of sudden death following -and death due to -coronary heart disease in adults. 
Physical activity recommendations
Time spent in front of TV, video games and computer should be limited to 2 h/day to prevent atherosclerosis, in addition to encouraging pleasing physical activity for 30 min/ day, 3 to 4 times a week. 14 A Brazilian study found prevalence of sedentary lifestyle in over 70% of the overweight children and adolescents.
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Physical activity seems to act on lipid profile; however, it is extremely difficult to methodologically assess physical activity in children and adolescents. Aerobic activity seems to be related to a decrease in the levels of triglycerides, total and LDL cholesterol, as well as to an increase in HDL-C levels. 2, 18, 19 Although these changes are of a modest nature, physical activity brings additional benefits, such as a reduction in body mass index, in blood pressure, and, consequently, a decrease in cardiovascular disease.
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Drug treatment of dyslipidemia
Joint statement
The NCEP 14 
Clinical trials
Primary dyslipidemia
Interventional studies in children with primary dyslipidemia were important to demonstrate drug safety, no interference with children's growth and development, and, mainly, reversion of functional vascular abnormalities by drug treatment. Dirisamer et al. 12 carried out a study with 20 adolescents, aged between 10 and 17 years, with diagnosis of familial hypercholesterolemia on simvastatin treatment for 1 year. LDL-C levels were reduced in 30% among those children receiving 5 mg/day, 30% among those receiving 10 mg/day, and 36% among those receiving 20 mg/day. Two patients showed raised creatine kinase enzymes and transaminases (alanine aminotransferase and aspartate aminotransferase). Side effects occurred during the first 4 weeks of treatment and disappeared up to the seventh day, and none of the patients had to be weaned off the treatment because of the side effects. 24 Thus, the use of statins in primary dyslipidemias seems scientifically safe; however, their use should always be evaluated against the balancing of costs and benefits to young patients.
Secondary dyslipidemia
Metabolic syndrome (MS) is a nutrition disorder that occurs in developed and developing countries with high prevalence in the adult population and a growing trend toward the pediatric population. [25] [26] [27] Prevalence of MS in American adolescents was identified in 6.8% of the overweight adolescents and in 28.7% of the obese adolescents. 28 A Brazilian study with obese children demonstrated the prevalence of MS to be 17.3% of the obese children aged between 7 and 10 years.
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MS is a complex disorder characterized by a set of cardiovascular risk factors usually related to central fatty deposits and insulin resistance. The disease components found in adults include: central obesity, hypertriglyceridemia, reduced serum HDL-C levels, high blood pressure, and high fasting glycemia. 29 Obesity is a severe risk factor for the development of dyslipidemia. Although criteria for the diagnosis of this syndrome in children and adolescents are yet to be defined, values of glucose, insulin resistance, triglycerides, C-reactive protein, interleukin-6, and systolic blood pressure raise significantly as obesity increases, along with a reduction in serum HDL-C and adiponectin levels. 30 The Bogalusa Heart Study demonstrated that obese school children are 2.4 to 7.1 times more likely to show high levels of total cholesterol, LDL-C and triglycerides, and 12.6 times more likely to have hyperinsulinemia. 5 A Brazilian study found that overweight children and adolescents are 2.8 times more likely to develop dyslipidemia. 34 Sun et al. 35 60% achieved LDL-C levels < 130 mg/dL, whereas none of the patients in the control group achieved this target LDL-C level after a 6-month follow-up. Therapy was well-tolerated and no side effects were observed regarding growth and development patterns. 37 Some individuals have conditions favorable to the development of high-risk lipid abnormalities. These conditions include: diabetes mellitus, chronic renal disease, heart transplant, Kawasaki disease, congenital heart disease, chronic inflammatory disease, cancer, and AIDS. 38 Type 1 diabetes is a metabolic disease characterized by a deficiency in insulin secretion causing hyperglycemia, which is associated as a primary factor in the development of atherosclerosis. It is a chronic renal disease that causes cardiac abnormalities, such as pericarditis, arrhythmias and ventricular dysfunction, which, in addition to uremia and hypertension, will increase the risk of developing atherosclerosis. Heart transplant children have some degree of atherosclerosis in the coronary arteries during the first year after transplantation.
Another disease that causes coronary changes, the Kawasaki disease, also predisposes children to early atherosclerotic disease. Systemic lupus erythematosus and rheumatoid arthritis are chronic inflammatory diseases associated with atherosclerosis because of the inflammation itself (which is part of the pathophysiology of atherosclerotic disease), as well as the corticoid therapy used for its treatment. Congenital Another risk group for early atherosclerotic disease is the HIV-infected children who use protease inhibitors.
Cross-sectional studies have shown an association of these drugs with hypercholesterolemia and hypertriglyceridemia. 40 Studies examining the incidence of hypercholesterolemia in children on protease inhibitors observed a raise in cholesterol levels throughout the treatment. 41 In the first prospective, longitudinal study to examine the inhibiting effects of protease on the HIV-infected pediatric population, in addition to the 13% who presented lipid profile changes, 13% developed hypercholesterolemia due to the treatment. 42 The manual for the treatment of AIDS-related dyslipidemia in adults recommends pravastatin or atorvastatin for patients with triglycerides between 200 and 500 mg/dL and gemfribozil for those with triglycerides > 500 mg/dL. Simvastatin and lovastatin should be avoided because of drug interaction with antiretroviral therapy. 43 Prospective studies showed effectiveness and safety in the use of statins (pravastatin, atorvastatin, simvastatin, and fluvastatin) and fibrates (bezafibrate, gemfribozil, fenofibrate, and ciprofibrate) for patients on antiretroviral therapy, with no changes in the levels of cluster of differentiation 4, viral load, creatine kinase, and transaminase, suggesting no interaction with the antiretroviral therapy. 44, 45 In view of the foregoing, it becomes evident that prevention of atherosclerosis and its repercussions on the cardiovascular system should begin in childhood. It seems that dietary treatment is not enough to stop disease progression in severe cases, highlighting the need for drug therapy associated with a dietary treatment to halt disease progression.
New recommendations for drug treatment of children and adolescents with dyslipidemia
Some theories claim that pediatric treatment is not as effective or safe to reduce morbidity and mortality in adults as suggested. However, the 1992 statement does not take into account high-risk children with family history of parents with early cardiovascular disease and/or hypercholesterolemia, the ones who can benefit from drug treatment at an early age.
Additionally, drug treatment is based only on LDL-C levels and does not take into account other risk factors for atherosclerotic disease. mg/day for those aged 14-18 years. 4 Reduction in LDL-C levels varies from 21 to 41%. 2 Rosuvastatin, a new statin, proved to be effective and safe in the treatment against hyperlipidemia in adults with primary dyslipidemia, though studies with children are currently lacking.
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Nicotinic acid
Nicotinic acid is a soluble vitamin, whose action remains under study, which lowers triglycerides and LDL-C levels and raises HDL-C levels. It is rarely used for treatment in the pediatric population because of the high incidence of adverse effects, such as diarrheic disease, and other more severe side effects, such as glucose intolerance, myopathy, hyperuricemia and fulminant liver failure.
Fibrates
Fibrates are fibric acid derivatives, with a complex mechanism of action, which decrease triglyceride levels and increase HDL-C levels. They can also reduce LDL-C levels. 
Statin treatment
The AHA 2 developed a manual to guide the use of statins in children, whose summary is found in Table 2 Some studies have demonstrated safety and effectiveness of statin treatment in children; however, due to the lack of long-term studies, these recommendations should be used carefully.
Final considerations
The pediatrician plays a crucial role in the prevention and treatment of atherosclerosis. Keeping a healthy lifestyle should be encouraged from childhood as the basis of the prevention of atherosclerotic disease and its comorbidities, which have affected the population at an earlier age.
Evidence from studies on the drug treatment of children with primary dyslipidemia shows safety and effectiveness similar to that found in the treatment of adults. Dated statements show limitations, mainly because they could not approach the recent childhood overweight and obesity epidemic. These new recommendations include additional risk factors involved in the pathophysiology of atherosclerosis.
They point out that drug treatment should be used only in children with high-risk lipid abnormalities, or other associated high-risk conditions that do not respond to changes of lifestyle, and should not be used as first-line treatment.
Conclusions
It is important to highlight that drug treatment should be used only in patients with severe lipid abnormalities, in
Prevention and treatment of atherosclerosis -de Castro PS & Oliveira FL patients with high-risk conditions who did not meet their lipid-lowering goals through diet and lifestyle approaches, or when these changes are not directly related to the patient's lifestyle. Pediatricians should use their scientific knowledge to improve the quality of life of their patients, always keeping in mind the binomial benefits/risks for the pediatric patient in the short, medium and long term. 2) Start with the lowest dose a day, before going to bed. Perform serum creatine kinase, ALT and AST measurements.
3) Guide patients on adverse affects, especially myopathies. If myopathy occurs, evaluate its relation with physical activity; withdraw medication and perform serum creatine kinase measurement. Treatment can be resumed when symptoms and laboratory changes disappear.
4) Alert adolescents to the use of contraceptive methods.
5) Alert to drug interactions, especially with cyclosporine, fibrates, niacin, erythromycin, azole antifungals, nefazodone, and protease inhibitors.
6) After 4 weeks, monitor serum creatine kinase, AST and ALT measurements, and compare them to baseline levels. Serum creatine kinase levels 10 times higher than the upper limit should be investigated (take into account the impact of physical activity), as well as ALT and AST three times higher than the upper limit. The minimum acceptable LDL-C concentration should be less than 130 mg/dL, and the ideal concentration should be less than or equal to 110 mg/dL.
7)
If the desirable LDL-C concentration is achieved and no laboratory changes are observed, continue treatment and monitor biochemical examinations every 8 weeks and, subsequently, every 3 months. 
